



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



**PF-05221304**

Item No. 36856

**CAS Registry No.:** 1370448-25-1  
**Formal Name:** 4-[6-methoxy-4-[[[1,4,6,7-tetrahydro-1-(1-methylethyl)-7-oxospiro[5H-indazole-5,4'-piperidin]-1'-yl]carbonyl]-2-pyridinyl]-benzoic acid  
**Synonym:** Clesacostat  
**MF:** C<sub>28</sub>H<sub>30</sub>N<sub>4</sub>O<sub>5</sub>  
**FW:** 502.6  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 255, 311 nm  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

PF-05221304 is supplied as a solid. A stock solution may be made by dissolving the PF-05221304 in the solvent of choice, which should be purged with an inert gas. PF-05221304 is soluble in DMSO.

## Description

PF-05221304 is an inhibitor of acetyl-CoA carboxylase 1 (ACC1) and ACC2 (IC<sub>50</sub>s = 12.4 and 8.7 nM, respectively).<sup>1</sup> It inhibits *de novo* lipid synthesis (IC<sub>50</sub> = 61 nM) and increases fatty acid oxidation in primary human hepatocytes. PF-05221304 reduces the accumulation of triglycerides composed of *de novo*-derived fatty acids but not dietary essential fatty acids in primary human hepatocytes. *In vivo*, PF-05221304 (10 and 100 mg/kg) reduces hepatic malonyl-CoA production and *de novo* lipogenesis in rats. It reduces hepatic fibrosis, alanine transaminase (ALT) and aspartate aminotransferase (AST) levels, and triglyceride accumulation in a rat model of non-alcoholic steatohepatitis (NASH) induced by a choline-deficient and high-fat diet (CDAHFD).

## Reference

1. Ross, T.T., Crowley, C., Kelly, K.L., *et al.* Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems. *Cell. Mol. Gastroenterol. Hepatol.* **10(4)**, 829-851 (2020).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/02/2023

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM